The prevalence of diabetes mellitus (DM) and associated diseases such as cancers are substantially increasing worldwide. About 80% of the patients with pancreatic cancer have glucose metabolism alterations. This suggests an association between type 2 DM and pancreatic cancer risk and progression. There are hypotheses that show metabolic links between the diseases, due to insulin resistance, hyperglycemia, hyperinsulinemia, low grade chronic inflammation, and alteration in the insulin-insulin-like growth factor axis. The use of diabetes medications can influence the extent of carcinogenesis of the pancreas. This study briefly reviews recent literature on investigation of metabolic link of type 2 DM, risk of carcinogenesis of the pancreas and their association, as well as the current understanding of metabolic pathways implicated in metabolism and cellular growth. The main finding of this review, although there are discrepancies, is that according to most research long-term DM does not raise the risk of pancreatic cancer. The longest duration of DM may reflect hypoinsulinemia due to treatment for hyperglycemia, but recent onset diabetes was associated with increased risk for pancreatic cancer due to hyperinsulinemia and hyperglycemia. In conclusion, the review demonstrates that type 2 DM and the duration of diabetes pose a risk for pancreatic carcinogenesis, and that there is biological link between the diseases. (Korean J Gastroenterol 2016;67:168-177) Key Words: Type 2 diabetes mellitus; Pancreatic neoplasms CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders of multiple etiologies characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, action, or both. 1 Several pathogenic processes are involved in the development of DM. These range from autoimmune destruction of the cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action.
Deficient insulin action results from inadequate insulin secretion and diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Longitudinal and cross-sectional studies have demonstrated that the earliest detectable abnormality in T2DM is an impairment of the body's ability to respond to insulin.
Genetic susceptibility and environmental factors are the most likely triggers of T2DM. 4, 5 The main function of the pancreas is to produce endocrine hormones and digestive enzymes that help break down carbohydrates, fats and proteins. The link between diabetes and cancer exists because T2DM is associated with increased insulin production; insulin causes the growth of cells and the proliferation of blood vessels in the pancreas that generates a hospitable environment for tumor formation. 6 Pancreatic cancer (PC) is a malignant tumor of the pancreas, and one of the most tragic and least understood of cancers, affecting the cells that produce insulin and glucagon. 6 The majority of PC originates from the ductal epithelial cells of the exocrine portion of the pancreas. There is extensive interaction between the endocrine and exocrine portions of the pancreas during pancreatic carcinogenesis. 6 It is characterized by an increased incidence in Western industrialized countries, an extremely poor median survival of four to six months after diagnosis and with an overall five-year survival of less than 4%. 7 The incidence and number of deaths caused by PC have been gradually rising, although incidence and mortality of other common cancers have been declining. 8 Inability to detect PC at an early stage, its aggressiveness, and the lack of effective systemic therapy are responsible for the rapid death of PC patients. 9 The poor outcome is a strong motivation for epidemiological research designed at identifying and reducing risk factors for PC. Besides age and genetic risk factors, several lifestyle and environmental factors, such as smoking, obesity, low physical activity and alcohol consumption are associated with PC.
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T2DM is associated with PC, but it is unclear whether DM is a causal factor or the result of subclinical malignancy.
11
T2DM may directly promote the progression of PC by pancreatic duct enlargement and hypertension, as well as increased tumor size. Up to 80% of PC patients are either hyperglycemic or diabetic, both of which can be detected in the pre-symptomatic phase. Hyperglycemia and glucose tolerance aberrations may be the first easily testable clinical manifestation of DM.
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At question is whether coincidence of diabetes and the risk of certain cancers is largely due to shared risk factors, or whether diabetes itself, and the specific metabolic disorders typical of diabetes, increase the risk of some types of cancer. 13 The development of DM within a few years of a PC diagnosis suggests an effect of the tumor, whereas DM of longer duration is more likely to contribute to the development of cancer.
14 T2DM and PC are linked, but researchers have found it difficult to determine which influences the other. 15 Based on the findings from several retrospective and prospective observational studies, T2DM and glucose intolerance are fairly reliable, albeit somewhat debatable, risk factors for PC. 
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Adiponectin increases fatty acids oxidation, which lowers circulating free fatty acids and prevents IR, and it exerts an anti-atherosclerotic effect, while augmenting endothelial nitrous oxide production and protecting the vasculature by reducing platelet aggregation and vasodilation. 52 Apart from causing metabolic dysfunction, adiponectin deficiency may also contribute to cardiovascular disease, IR, and a wide array of cancers. 52 The decrement of adiponectin precedes the development of IR and myocardial infarction in humans; low levels of adiponectin are likely to be a causal component of those disorders. 53 A study in Pima Indians shows individuals with high levels of adiponectin were less likely to develop T2DM, 65 The bilateral causality between the diseases has been widely documented. 13, 67 Epidemiological studies clearly indicate that the risk of PC is increased in DM patients, but most studies focus on T2DM.
The recent increase in the prevalence of T2DM is thought to have contributed to a parallel rise in the incidence of PC. 68 Worldwide, the prevalence of cancer is difficult to establish because many areas do not have cancer registries, but in 2008 there were an estimated 12.4 million new cancer cases diagnosed. 69 The most commonly diagnosed cancers were those of the lung, breast, and colorectal, whereas the most common causes of cancer deaths were lung, stomach, pancreas and liver cancer. 69 It has long been known that PC is associated with DM, and recent studies have revealed that about 85% of patients diagnosed with PC have impaired glucose tolerance. A large prospective study in the United States (US) followed a cohort of 467,922 men and 588,321 women for 16 years who had no reported history of cancer. The results showed that independent of a high body mass, T2DM acts as a predictor of mortality from cancer of the colon, pancreas, female breast, male liver and bladder. 74 Even though there is a strong association between PC and DM, the temporal sequence is unclear. However, 1% of newly diagnosed DM patients greater than 50 years of age will contract PC within three years. 75 A population based retrospective cohort study in China showed that increased risk of developing cancer was found in both male and female T2DM patients with a standardized incidence ratio (SIR) of 1.331 (95% CI, 1.143-1.518) and independent studies, including 50 cohort and 39 case control studies, were examined. The overall summary RR was 1.97 (95% CI, 1.78-2.18) with marked heterogeneity that could not be clearly attributed to any subgroup analyses. The risk of PC was greatest early after the diagnosis of DM and remained elevated long after the diagnosis. The individual level RR ranged from 6.69 at less than 1 year to 1.36 at 10 years. 77, 78 A prospective study found an association between a history of DM and subsequent risk of cancer in Japan. In men, a 27% increase in the risk of total cancer incidence (hazard ratio The development of DM within a few years of a PC diagnosis suggests an effect of the tumor, whereas DM of longer duration is more likely to contribute to the development of PC. 14 In many studies, an association between long-standing DM and an increased rate of death from PC was observed.
Controversies also exist regarding the association of long-standing DM and PC; some epidemiological studies refute the possibility that long-standing DM is a risk factor for PC. [88] [89] [90] However, a similar study in the USA reported that long-standing DM increases the risk of PC by 40% to 100%. 84 Moreover, a review of studies examining the association between T2DM and PC suggests that long-standing DM is an etiologic factor for PC; new onset is its manifestation. There is a modestly elevated risk of PC among persons with long-standing DM. 83 In contrast, recent onset T2DM is associated with a four to seven-fold increase in risk of PC, such that 1% to 2% of patients with recent onset DM will develop PC within three years. 91 Using data from the General Practice Research
Database, a study in 2012 showed that DM was associated with an increased risk of PC but the risk is to newly diagnosed DM of less than two years. 92 DM individuals who had been diagnosed less than four years prior had a 50% greater risk of developing malignancy compared with individuals who had DM for over four years. These results support a strong causal association between recent T2DM and PC. 16, 77 This is in contrast to other findings that long-standing DM has higher risk of developing PC than short-term T2DM.
CONCLUSION
This review finds that T2DM and PC are common health problems, and an association between these diseases was demonstrated by several epidemiological studies. The relationships between PC and alterations in glucose metabolism are very complex. In many studies, an association between long-standing T2DM and an increased rate of subsequent death from PC was indicated, but controversies exist. Some epidemiological studies have excluded the possibility that long-standing DM is a risk factor for PC; rather recent onset contributed more to carcinogenesis. Some studies showed evidence that longstanding diabetes is an etiologic factor for PC, while new onset diabetes is its manifestation, but still there is discrepancy in the literature. The main finding of this review were that metformin has a protective effect on the development of PC and long term duration of DM was not a risk factor for PC. Most research reported that recent-onset diabetes was associated with increased risk for PC. In conclusion, it is believed that T2DM, duration of diabetes are risk factor for pancreatic carcinogenesis and there is metabolic link between the diseases.
RECOMMENDATION
In summary, the finding of the review recommends early 
